Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: Exosomes apheresis
Sophie Schröder
Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
Search for more papers by this authorRobert Epple
Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
Search for more papers by this authorAndre Fischer
Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
Cluster of Excellence “Multiscale Bioimaging: From Molecular Machines to Networks of Excitable Cells” (MBExC), University of Göttingen, Göttingen, Germany
Search for more papers by this authorCorresponding Author
Volker J. J. Schettler
Center of Nephrology Göttingen GbR, Göttingen, Germany
Correspondence
Volker J. J. Schettler, Nephrologisches Zentrum Göttingen GbR An der Lutter 24, D-37075 Göttingen, Germany.
Email: [email protected]
Search for more papers by this authorSophie Schröder
Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
Search for more papers by this authorRobert Epple
Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
Search for more papers by this authorAndre Fischer
Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Göttingen, Göttingen, Germany
Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
Cluster of Excellence “Multiscale Bioimaging: From Molecular Machines to Networks of Excitable Cells” (MBExC), University of Göttingen, Göttingen, Germany
Search for more papers by this authorCorresponding Author
Volker J. J. Schettler
Center of Nephrology Göttingen GbR, Göttingen, Germany
Correspondence
Volker J. J. Schettler, Nephrologisches Zentrum Göttingen GbR An der Lutter 24, D-37075 Göttingen, Germany.
Email: [email protected]
Search for more papers by this authorAbstract
Introduction
Extracellular vesicles (EVs) have been identified as playing a role in atherosclerosis.
Methods
A group of 37 hypercholesterolemic patients with atherosclerotic cardiovascular diseases (ASCVD) and 9 patients requiring hemodialysis (HD) were selected for the study.
Results
EVs were comparably reduced by various LA methods (Thermo: 87.66% ± 3.64, DALI: 87.96% ± 4.81, H.E.L.P.: 83.38% ± 11.98; represented as SEM). However, LDL-C (66%; 55%; 75%) and Lp(a) (72%; 67%; 79%) were less effectively reduced by DALI. There was no significant difference in the reduction of EVs when comparing different techniques, such as hemoperfusion (DALI; n = 13), a precipitation (H.E.L.P.; n = 5), and a double filtration procedure (Thermofiltration; n = 19). Additionally, no effect of hemodialysis on EVs reduction was found.
Conclusions
The study suggests that EVs can be effectively removed by various LA procedures, and this effect appears to be independent of the specific LA procedure used, as compared to hemodialysis.
CONFLICT OF INTEREST STATEMENT
Sophie Schröder, Robert Epple, Andre Fischer, and Volker J. J. Schettler have no disclosures with respect to this manuscript.
REFERENCES
- 1Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111–188. https://doi.org/10.1093/eurheartj/ehz455
- 2Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022; 43: 3925–3946. https://doi.org/10.1093/eurheartj/ehac361
- 3Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138: S419–S420. https://doi.org/10.1016/s0002-8703(99)70266-8
- 4Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules. 2023; 28: 28. https://doi.org/10.3390/molecules28030969
- 5Pfeiler S, Gerdes N. Atherosclerosis: cell biology and lipoproteins—focus on anti-inflammatory therapies. Curr Opin Lipidol. 2018; 29: 53–55. https://doi.org/10.1097/MOL.0000000000000481
- 6Engelen SE, Robinson AJB, Zurke YX, Monaco C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. 2022; 19: 522–542. https://doi.org/10.1038/s41569-021-00668-4
- 7Laval T, Ouimet M. A role for lipophagy in atherosclerosis. Nat Rev Cardiol. 2023; 20: 431–432. https://doi.org/10.1038/s41569-023-00885-z
- 8Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis. J Intern Med. 2008; 263: 528–537. https://doi.org/10.1111/j.1365-2796.2008.01957.x
- 9Giro O, Jimenez A, Pane A, Badimon L, Ortega E, Chiva-Blanch G. Extracellular vesicles in atherothrombosis and cardiovascular disease: friends and foes. Atherosclerosis. 2021; 330: 61–75. https://doi.org/10.1016/j.atherosclerosis.2021.07.002
- 10Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367: 367. https://doi.org/10.1126/science.aau6977
- 11Konkoth A, Saraswat R, Dubrou C, Sabatier F, Leroyer AS, Lacroix R, et al. Multifaceted role of extracellular vesicles in atherosclerosis. Atherosclerosis. 2021; 319: 121–131. https://doi.org/10.1016/j.atherosclerosis.2020.11.006
- 12Safarova MS, Moriarty PM. Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a). Curr Atheroscler Rep. 2023; 25: 391–404. https://doi.org/10.1007/s11883-023-01113-2
- 13Schatz U, Schettler VJJ, Julius U. State of the art: lipoprotein apheresis. Dtsch Med Wochenschr. 2023; 148: e44–e54. https://doi.org/10.1055/a-1516-2761
- 14Schettler VJJ, Peter C, Zimmermann T, Julius U, Roeseler E, Schlieper G, et al. The German lipoprotein apheresis registry-summary of the ninth annual report. Ther Apher Dial. 2022; 26(Suppl 1): 81–88. https://doi.org/10.1111/1744-9987.13780
- 15Schettler VJJ, Schettler E. Beyond cholesterol-pleiotropic effects of lipoprotein apheresis. Ther Apher Dial. 2022; 26(Suppl 1): 35–40. https://doi.org/10.1111/1744-9987.13857
- 16Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, et al. Lipoprotein apheresis in Germany - still more commonly indicated than implemented. How can patients in need access therapy? Atheroscler Suppl. 2019; 40: 23–29. https://doi.org/10.1016/j.atherosclerosissup.2019.08.038
- 17Klingel R, Heigl F, Schettler V, Roeseler E, Grützmacher P, Hohenstein B, et al. Lipoprotein(a)—marker for cardiovascular risk and target for lipoprotein apheresis. Atheroscler Suppl. 2019; 40: 17–22. https://doi.org/10.1016/j.atherosclerosissup.2019.08.037
- 18Park S, Lee K, Park IB, Kim NH, Cho S, Rhee WJ, et al. The profiles of microRNAs from urinary extracellular vesicles (EVs) prepared by various isolation methods and their correlation with serum EV microRNAs. Diabetes Res Clin Pract. 2020; 160:108010. https://doi.org/10.1016/j.diabres.2020.108010
- 19Ray KK, Ference BA, Severin T, Blom D, Nicholls SJ, Shiba MH, et al. World heart federation cholesterol roadmap 2022. Glob Heart. 2022; 17: 75. https://doi.org/10.5334/gh.1154
- 20Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022; 399: 1347–1358. https://doi.org/10.1016/S0140-6736(21)02391-6
- 21Marx N, Federici M, Schutt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 2023: 4043–4140. https://doi.org/10.1093/eurheartj/ehad192
10.1093/eurheartj/ehad192 Google Scholar
- 22Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021; 77: 1439–1450. https://doi.org/10.1016/j.jacc.2021.01.027
- 23Farukhi ZM, Mora S. Lipoprotein(a) association with residual risk: what has inflammation got to do with it? Eur Heart J. 2024; 45: 1055–1057. https://doi.org/10.1093/eurheartj/ehae045
- 24Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015; 36: 2635–2642. https://doi.org/10.1093/eurheartj/ehv236
- 25Wieland E, Schettler V, Armstrong VW. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis. 2002; 162: 187–191. https://doi.org/10.1016/s0021-9150(01)00698-0
- 26Wang H, Xie Y, Salvador AM, Zhang Z, Chen K, Li G, et al. Exosomes: multifaceted messengers in atherosclerosis. Curr Atheroscler Rep. 2020; 22: 57. https://doi.org/10.1007/s11883-020-00871-7
- 27Boulanger CM, Loyer X, Rautou PE, Amabile N. Extracellular vesicles in coronary artery disease. Nat Rev Cardiol. 2017; 14: 259–272. https://doi.org/10.1038/nrcardio.2017.7
- 28Patel S, Guo MK, Abdul Samad M, Howe KL. Extracellular vesicles as biomarkers and modulators of atherosclerosis pathogenesis. Front Cardiovasc Med. 2023; 10:1202187. https://doi.org/10.3389/fcvm.2023.1202187
- 29Zhou R, Bozbas E, Allen-Redpath K, Yaqoob P. Circulating extracellular vesicles are strongly associated with cardiovascular risk markers. Front Cardiovasc Med. 2022; 9:907457. https://doi.org/10.3389/fcvm.2022.907457
- 30Li T, Wang B, Ding H, Chen S, Cheng W, Li Y, et al. Effect of extracellular vesicles from multiple cells on vascular smooth muscle cells in atherosclerosis. Front Pharmacol. 2022; 13:857331. https://doi.org/10.3389/fphar.2022.857331
- 31Schettler V, Monazahian M, Wieland E, Thomssen R, Müller GA. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther Apher. 2001; 5: 384–386. https://doi.org/10.1046/j.1526-0968.2001.00374.x
- 32Connolly KD, Willis GR, Datta DB, Ellins EA, Ladell K, Price DA, et al. Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia. J Lipid Res. 2014; 55: 2064–2072. https://doi.org/10.1194/jlr.M049726
- 33Dlouha D, Blaha M, Blaha V, Fatorova I, Hubacek JA, Stavek P, et al. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis. Atheroscler Suppl. 2017; 30: 128–134. https://doi.org/10.1016/j.atherosclerosissup.2017.05.037
- 34Dlouha D, Blaha M, Huckova P, Lanska V, Hubacek JA, Blaha V. Long-term LDL-apheresis treatment and dynamics of circulating miRNAs in patients with severe familial hypercholesterolemia. Genes. 2023; 14. https://doi.org/10.3390/genes14081571
Citing Literature
